Neuland Laboratories
NEULANDLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Davuluri Rama Mohan Rao · MD: Davuluri Saharsh Rao · Listing date: Oct. 14, 2008 · Employees: 1427 · Hyderabad · http://www.neulandlabs.com

Stock Price vs Company Growth
1d
3.7%
1w
9.2%
1m
6.5%
3m
9.0%
6m
112.2%
1y
171.2%
5y
101.8%
10y
41.0%
all
36.8%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 13,901 3.7%
10,791
18,090
Company Overview

Sales
1,528 Cr
Growth: 18.9%
Profit after Tax
259 Cr
Growth: -17.9%
Mid Cap
17,835 Cr
P/E: 63.8x
Industry P/E: 37.3x
Fundamentals

Sales (Cr) ₹ 1,528
Growth 18.9%
EBITDA 27.1%
P/S 11.7x
Dividend 0.3%
P/E 63.8x
Book Value ₹ 1,085
PEG Ratio 3.4x
ROE 19.7%
P/B 12.8x
Shareholding Pattern

Institutions
Malabar India Fund Limited
9.95 %
Malabar Value Fund
4.29 %
Matthews India Fund
2.55 %
Icg Q Limited
1.76 %
Promoters
Ramamohan Rao Davuluri
24.97 %
Davuluri Vijaya Rao
4.78 %
Davuluri Sucheth Rao
2.63 %
Davuluri Saharsh Rao
1.98 %
Davuluri Rohini Niveditha Rao
1.27 %
Others
Mukul Mahavir Agrawal
2.34 %
Kedia Securities Private Limited
1.01 %
Iepf
0.21 %
Increase    Decrease    No change
Company Profile Detailed

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.
Investors (89)
Followers (2)